jak2  (Proteintech)

Journal: Pharmaceutical Science Advances

Article Title: Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways

doi: 10.1016/j.pscia.2026.100121

Figure Lengend Snippet: FHF provided therapeutic benefit in JAK2 V617F -induced MPN mice. (A) Schematic diagram of the JAK2 V617F -driven MPN mice and therapeutic intervention. Transplantation donors of bone marrow cells expressing JAK2 V617F were treated with vehicle or FHF for 6 weeks. (B) RBC, HGB, and HCT counts in PB from indicated mice after treatment. N = 6 mice per group. (C) Results of flow cytometry analysis of TER119 + cells in bone marrow. (D) Spleen size and weight of indicated mice after FHF treatment. (E-G) Representative H&E staining of spleen, BM and lung.

Article Snippet: JAK2 V617F -floxed mice and Vav-Cre mice were obtained from the Jackson Laboratory.

Techniques: Transplantation Assay, Expressing, Flow Cytometry, Staining

Journal: Pharmaceutical Science Advances

Article Title: Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways

doi: 10.1016/j.pscia.2026.100121

Figure Lengend Snippet: Schematic illustration of FHF treatment for MPNs. FHF treatment inhibits the JAK2/STAT3 and NF-κB signaling pathways. This suppresses the expression of pro-inflammatory cytokines and cell proliferation. On the other hand, FHF promotes cellular senescence by activating the p53/p21 signaling pathway.

Article Snippet: JAK2 V617F -floxed mice and Vav-Cre mice were obtained from the Jackson Laboratory.

Techniques: Protein-Protein interactions, Expressing

Journal: Molecular Medicine Reports

Article Title: Long non-coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF-β1-mediated renal fibrosis

doi: 10.3892/mmr.2026.13839

Figure Lengend Snippet: JKA2/STAT3 pathway protein detection in HK-2 cells transfected with LncRNA NKILA overexpression virus (A) Representative western blotting bands and (B) semi-quantification of results of protein expression of phosphorylated JAK2 and STAT3 (n=3). (C) RT-qPCR statistical results (n=3). ## P<0.01 and # P<0.05 compared with the normal group. ns, not significant; p-, phosphorylated; OE, overexpression; NC, negative control; JAK, Janus kinase; RT-qPCR, reverse transcription quantitative PCR.

Article Snippet: After blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies against fibronectin (FN; 1:1,000; cat. no. ab45688; Abcam), collagen I (Col1; 1:1,000; cat. no. ab138492; Abcam), vimentin (Vim; 1:1,000; cat. no. 10366-1-AP; Proteintech Group, Inc.), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. 14395-1-AP; Proteintech Group, Inc.), JAK2 (1:1,000; cat. no. 17670-1-AP; Proteintech Group, Inc.), STAT3 (1:1,000; cat. no. 10253-2-AP; Proteintech Group, Inc.), phosphorylated (p)-JAK2 (1:500; cat. no. ab32101; Abcam), p-STAT3 (1:500; cat. no. ab76315; Abcam) and GAPDH (1:5,000; cat. no. 10494-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Over Expression, Virus, Western Blot, Expressing, Quantitative RT-PCR, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Molecular Medicine Reports

Article Title: Long non-coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF-β1-mediated renal fibrosis

doi: 10.3892/mmr.2026.13839

Figure Lengend Snippet: JAK2/STAT3 signaling pathway-associated proteins in HK-2 cells transfected with LncRNA NKILA knockdown lentivirus (A) Representative western blotting bands and (B) semi-quantification of JAK2/STAT3 pathway protein expression (n=3). (C) Statistical analysis results of reverse transcription-quantitative PCR for channel indicators. ## P<0.01 compared with the normal group (n=3), **P<0.01 and *P<0.05 compared with the control + KD-NC group. JAK, Janus kinase; KD, knockdown; NC, negative control; p-, phosphorylated.

Article Snippet: After blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies against fibronectin (FN; 1:1,000; cat. no. ab45688; Abcam), collagen I (Col1; 1:1,000; cat. no. ab138492; Abcam), vimentin (Vim; 1:1,000; cat. no. 10366-1-AP; Proteintech Group, Inc.), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. 14395-1-AP; Proteintech Group, Inc.), JAK2 (1:1,000; cat. no. 17670-1-AP; Proteintech Group, Inc.), STAT3 (1:1,000; cat. no. 10253-2-AP; Proteintech Group, Inc.), phosphorylated (p)-JAK2 (1:500; cat. no. ab32101; Abcam), p-STAT3 (1:500; cat. no. ab76315; Abcam) and GAPDH (1:5,000; cat. no. 10494-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Knockdown, Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Control, Negative Control

Journal: Molecular Medicine Reports

Article Title: Long non-coding RNA NKILA regulates the JAK2/STAT3 pathway to exacerbate TGF-β1-mediated renal fibrosis

doi: 10.3892/mmr.2026.13839

Figure Lengend Snippet: JAK2/STAT3 pathway protein detection in the recovery experiment of HK-2 cells treated with AG490. (A) Representative western blotting bands and (B) semi-quantification of JAK2/STAT3 pathway protein expression (n=3). (C) Reverse transcription-quantitative PCR for channel indicators (n=3). ## P<0.01 compared with the normal group, **P<0.01 and *P<0.05 compared with control + DMSO group and △△ P<0.01 compared with OE-NKILA group. OE, overexpression; p-, phosphorylated; JAK, Janus kinase; ns, not significant.

Article Snippet: After blocking with 5% non-fat milk for 2 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies against fibronectin (FN; 1:1,000; cat. no. ab45688; Abcam), collagen I (Col1; 1:1,000; cat. no. ab138492; Abcam), vimentin (Vim; 1:1,000; cat. no. 10366-1-AP; Proteintech Group, Inc.), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. 14395-1-AP; Proteintech Group, Inc.), JAK2 (1:1,000; cat. no. 17670-1-AP; Proteintech Group, Inc.), STAT3 (1:1,000; cat. no. 10253-2-AP; Proteintech Group, Inc.), phosphorylated (p)-JAK2 (1:500; cat. no. ab32101; Abcam), p-STAT3 (1:500; cat. no. ab76315; Abcam) and GAPDH (1:5,000; cat. no. 10494-1-AP; Proteintech Group, Inc.).

Techniques: Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Control, Over Expression

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: Effect of BG on JAK2/STAT3/HMGB1 signaling pathway in LPS-induced BV2. (A) Quantification of the p-JAK2/JAK2 in LPS-induced BV2 (n = 3). (B) Quantification of the p-STAT3/STAT3 in LPS-induced BV2 (n = 3). (C) Quantification of the HMGB1 in LPS-induced BV2 (n = 3). (D) Quantification of the HMGB1 in the cytoplasm in LPS-induced BV2 (n = 3). (E) Quantification of the HMGB1 in the nucleus in LPS-induced BV2 (n = 3). Compared with the control group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the BG-10 μg/mL group, △ p < 0.05, △△ p < 0.01, △△△ p < 0.001.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: Effect of BG on JAK2/STAT3/HMGB1 signalling pathway in brain tissue of MCAO rats. (A–C) Expression of HMGB1 in brain, lung tissues and serum (n = 6). (D) Quantification of the p-JAK2/JAK2 in brains (n = 3). (E) Quantification of the p-STAT3/STAT3 in brains (n = 3). (F) Quantification of the HMGB1 in brains (n = 3). (G) Quantification of the HMGB1 in the cytoplasm in brains (n = 3). (H) Quantification of the HMGB1 in the nucleus in brains (n = 3). (I) Immunofluorescence assay of HMGB1 in brain tissues. Compared with the sham group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the BG-25 mg/kg group, △ p < 0.05, △△ p < 0.01.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Expressing, Immunofluorescence

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: In LPS-induced BV2, BG reduces JAK2 activation and blocks the JAK2-STAT3-HMGB1 pathway, thereby reducing the inflammatory response. (A) Quantification of the p-JAK2/JAK2 in BV2 (n = 3). (B) Quantification of the p-STAT3/STAT3 in BV2 (n = 3). (C) Quantification of the HMGB1 in BV2 (n = 3). (D) Immunofluorescence assay of HMGB1. Compared with the control group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05; compared with the BG-50 μg/mL group, △ p < 0.05, △△ p < 0.01; compared with the CA1 group, ○ p < 0.05, ○○ p < 0.01.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Activation Assay, Immunofluorescence, Control

Journal: Immunity, Inflammation and Disease

Article Title: Ginkgolide B Alleviates Airway Inflammation in Hyperoxia Lung Injury

doi: 10.1002/iid3.70364

Figure Lengend Snippet: Western blot detection of Jak2, Stat3, and phosphorylation. (A) Western blot images of Jak2, Stat3, p‐Jak2, and p‐Stat3 in rat lung tissue in three groups. (B) Protein relative expressions of Jak2, Stat3, p‐Jak2, and p‐Stat3 in rat lung tissue in three groups using Image J software. Six rats per group, repeated three times in each experiment, and the data were pooled. Room air ( n = 3–7), hyperoxia ( n = 6–7), hyperoxia +GB ( n = 3–6).

Article Snippet: PhosphoPlus Jak2 (Tyr1007/Tyr1008) Antibody Duet , Cell Signaling Technology TM , 8224S , 1:1000.

Techniques: Western Blot, Phospho-proteomics, Software